Bill
Bill > HB920
LA HB920
LA HB920Requires drug manufacturers to limit pricing of GLP-1 medications for health insurance plans (OR INCREASE GF EX See Note)
summary
Introduced
02/27/2026
02/27/2026
In Committee
03/09/2026
03/09/2026
Crossed Over
Passed
Dead
Introduced Session
2026 Regular Session
Bill Summary
AN ACT To enact R.S. 22:1034.2 and Part IX of Chapter 5-E of title 40 of the Louisiana Revised Statutes of 1950, to
AI Summary
This bill requires drug manufacturers to limit the pricing of Glucagon-Like Peptide-1 (GLP-1) medications for health insurance plans in Louisiana. GLP-1 medications are a type of drug that helps control blood sugar, digestion, and appetite, and can be taken as injections or orally. The bill establishes that health coverage plans cannot require an insured person to pay more than $200 for a 30-day supply of a GLP-1 medication, regardless of the specific dosage or type of medication prescribed. Additionally, the bill mandates that the Louisiana Medicaid program will cover GLP-1 medications for eligible individuals when prescribed by a provider, irrespective of their specific medical condition or diagnosis, and allows the Louisiana Department of Health to pursue federal approvals if necessary to implement this coverage.
Committee Categories
Business and Industry
Sponsors (1)
Last Action
Read by title, under the rules, referred to the Committee on Insurance. (on 03/09/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.legis.la.gov/legis/BillInfo.aspx?s=26rs&b=HB920&sbi=y |
| Fiscal Note - HB920 Original | https://www.legis.la.gov/Legis/ViewDocument.aspx?d=1462517 |
| Analysis - Digest of HB920 Original | https://www.legis.la.gov/Legis/ViewDocument.aspx?d=1447619 |
| BillText | https://www.legis.la.gov/Legis/ViewDocument.aspx?d=1447607 |
Loading...